NASDAQ:KROS Keros Therapeutics Q4 2024 Earnings Results & Report $11.95 +0.31 (+2.66%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$11.98 +0.03 (+0.21%) As of 10/9/2026 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Keros Therapeutics beat analyst earnings expectations but missed on revenue in its Q4 2024 results, released February 26, 2025. The company reported EPS of -$1.14 versus the -$1.36 consensus estimate, while revenue of $3.04 million fell short of the $37.32 million estimate by $34.28 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 26, 2025TimeBefore Market OpensConference Call4:00 PM ET Keros Therapeutics EPS ResultsActual EPS-$1.14Consensus EPS -$1.36Beat/MissBeat by +$0.22One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersKeros Therapeutics Revenue ResultsActual Revenue$3.04 millionExpected Revenue$37.32 millionBeat/MissMissed by -$34.28 millionYoY Revenue GrowthN/AUpcoming EarningsKeros Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Keros Therapeutics Q4 2024 Earnings FAQ Did Keros Therapeutics beat earnings estimates for Q4 2024? Keros Therapeutics (NASDAQ:KROS) reported earnings of -$1.14 per share for Q4 2024, beating the consensus estimate of -$1.36. The report was announced on Wednesday, February 26, 2025. What was Keros Therapeutics' revenue for Q4 2024? Keros Therapeutics reported revenue of $3.04 million for Q4 2024, against a consensus estimate of $37.32 million. When is Keros Therapeutics' next earnings date? Keros Therapeutics' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Keros Therapeutics on the company's earnings history page. Keros Therapeutics Earnings HeadlinesKeros Therapeutics (NASDAQ:KROS) Stock Rating Raised to Sell at Wall Street ZenOctober 10 at 1:25 AM | americanbankingnews.comReviewing Upstream Bio (NASDAQ:UPB) & Keros Therapeutics (NASDAQ:KROS)October 5, 2026 | americanbankingnews.comThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.October 10 at 1:00 AM | TradeSmith (Ad)Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in PlaySeptember 30, 2026 | tipranks.comKeros Therapeutics Expects $20 Million Milestone Payment From TakedaSeptember 29, 2026 | finance.yahoo.comKeros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 TrialSeptember 29, 2026 | quiverquant.comQSee More Keros Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email. Email Address About Keros TherapeuticsKeros Therapeutics (NASDAQ:KROS) is a clinical-stage biopharmaceutical company focused on developing therapies that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. These biological pathways influence blood-cell production, bone health, muscle growth and cardiovascular function, and may play a role in several serious diseases. The company’s investigational portfolio has included elritercept (KER-050), an engineered ligand trap designed to enhance red blood cell production and address anemia associated with conditions such as myelodysplastic syndromes and myelofibrosis. Keros has also developed cibotercept (KER-012), an investigational therapy designed to modulate activin signaling for potential use in pulmonary arterial hypertension and other cardiovascular conditions. Its research activities have included additional compounds targeting pathways involved in muscle and metabolic disorders. Founded in 2015 and headquartered in Lexington, Massachusetts, Keros conducts drug discovery and clinical-development activities primarily through studies in the United States and other regions as appropriate for its programs. The company’s work is focused on advancing proprietary biologic medicines from preclinical research through clinical testing and, if successful, regulatory approval.View Keros Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
